Home › Compare › APLIF vs XYLD

APLIF vs XYLD: Dividend Comparison 2026

APLIF yields 18181.82% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APLIF wins by $20382968138483965952.00M in total portfolio value
10 years
APLIF
APLIF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20382968138483965952.00M
Annual income
$20,164,798,479,641,134,000,000,000.00
Full APLIF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — APLIF vs XYLD

📍 APLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPLIFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APLIF + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
APLIF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLIF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$17,140,078,707,694,964,000,000,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, APLIF beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLIF + XYLD for your $10,000?

APLIF: 50%XYLD: 50%
100% XYLD50/50100% APLIF
Portfolio after 10yr
$10191484069241982976.00M
Annual income
$10,082,399,239,820,567,000,000,000.00/yr
Blended yield
98.93%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLIF buys
0
XYLD buys
0
No recent congressional trades found for APLIF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPLIFXYLD
Forward yield18181.82% ✓10.98%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$20382968138483965952.00M ✓$25.3K
Annual income after 10y$20,164,798,479,641,134,000,000,000.00 ✓$3,219.02
Total dividends collected$20368560651224936448.00M ✓$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: APLIF vs XYLD ($10,000, DRIP)

YearAPLIF PortfolioAPLIF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$1,828,882$1,818,181.82$10,818$1,098.39+$1.82M → APLIF
2$312,726,966$310,770,062.56$11,738$1,222.51+$312.72M → APLIF
3$49,997,862,140$49,663,244,286.24$12,774$1,364.64+$49997.85M → APLIF
4$7,474,070,205,933$7,420,572,493,443.65$13,944$1,527.86+$7474070.19M → APLIF
5$1,044,712,232,322,833$1,036,714,977,202,484.10$15,270$1,715.87+$1044712232.31M → APLIF
6$136,547,911,758,351,100$135,430,069,669,765,680.00$16,775$1,933.09+$136547911758.33M → APLIF
7$16,689,313,388,956,088,000$16,543,207,123,374,653,000.00$18,490$2,184.87+$16689313388956.07M → APLIF
8$1,907,542,220,817,720,100,000$1,889,684,655,491,537,200,000.00$20,450$2,477.63+$1907542220817720.25M → APLIF
9$203,896,877,423,206,970,000,000$201,855,807,246,932,000,000,000.00$22,697$2,819.19+$203896877423206976.00M → APLIF
10$20,382,968,138,483,967,000,000,000$20,164,798,479,641,134,000,000,000.00$25,280$3,219.02+$20382968138483965952.00M → APLIF

APLIF vs XYLD: Complete Analysis 2026

APLIF — Stock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Full APLIF Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this APLIF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLIF vs SCHDAPLIF vs JEPIAPLIF vs OAPLIF vs KOAPLIF vs MAINAPLIF vs QYLDAPLIF vs JEPQAPLIF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.